Academic Drug Discovery Symposium

CD3-DDC symposium "Academic Drug Discovery: Challenges and Perspectives"

Imperial College on March 31st 2011.

Time	Speaker	Title	Links to talks
09:00-09:30		Registration
09:30-09:40	The Rector, Sir Keith O'Nions	Introduction
09:40-09:45	Prof Maggie Dallman	Chair SESSION 1 CD3
09:45-09:55	Prof Charles Coombes	CD3 Introduction	Coombes
09:55-10:25	Dr Matt Fuchter	Chemical Innovation in Drug Discovery	Fuchter
10:25-10:55	Prof Simak Ali	The design of novel cyclin dependent kinase inhibitors	Ali
10:55-11:25	Prof Bob Brown	New challenges in using biological endpoints for epigenetic therapies in clinical trials	Brown
11:25-11:55		Coffee Break
11:55-12:00	Prof Sir Anthony Newman-Taylor	Chair SESSION 2 KEYNOTE
12:00-13:00	Prof Paul Workman (ICR)	Drugging the cancer genome: The challenges of professional drug discovery in an academic environment	Workman
13:00-14:00		Lunch break
14:00-14:05	Prof Paul Freemont	Chair SESSION 3 DDC
14:05-14:35	Dr Cathy Tralau-Stewart	The Imperial Drug Discovery Centre: Introduction	Tralau
14:35-15:05	Drs Oliver Billker / Katie Chapman	CDPKs and Malaria: Screening approaches for identification of a chemical start point for drug discovery	Billker Chapman
15:05-15:35	Drs David Mann / Caroline Low	CDC25 and cancer: Molecular modeling appraoches for identifcation of a chemical start point for drug discovery	Mann & Low
15:35-16:05	Prof Guido Franzoso	A new peptide appraoch to multiple myeloma
16:05-16:35		Coffee Break
16:35-16:40	Prof Martin Wilkins	Chair SESSION 4 KEYNOTE
16:40-17:40	Prof Chase Bountra (SGC, Oxford)	Epigenetic protein structures, chemical probes and target discovery - all open access	Bountra
		Meeting close
17:40-19:00		Wine and networking